Aurealis Therapeutics Accelerates Oncology Program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago

Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has […]

Aurealis Therapeutics is attending the Swiss Biotech Day 2023

Juha Yrjänheikki (CEO) and Laurent Décory (COO) will be attending the Swiss Biotech Day 2023 which will take place from 24-25 April in Basel, Switzerland. This will be a fantastic opportunity to meet investors and discuss potential partnerships with pharma companies. The Swiss Biotech Day is one of the leading biotechnology conferences in Europe offering […]

Aurealis Therapeutics Novel Chronic Wound Treatment to be Presented at the 4th Experts Meeting on Microbiome & Skin Health and Disease on December 15th, 2020

Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for Tuesday, December 15th, 2020 at 14:30 CET. More […]

Aurealis Therapeutics to present at the European Wound Management Association Congress 2018

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company´s progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at the European Wound Management Association (EWMA) Congress in Krakow, Poland […]

Aurealis Therapeutics to attend the Swiss Biotech Day 2018

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company´s progress at the Swiss Biotech Day in Basel on May 3rd 2018. The Swiss Biotech Day has long become the standard […]

Aurealis Therapeutics to present at the 11th Annual European Life Sciences CEO Forum & Exhibition

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on February 26-27th 2018. The presentation is scheduled for Monday, February […]

Aurealis Therapeutics to present at Swiss Nordic Bio 2018

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018. The presentation is scheduled for: Time: Thursday, February 8th 2018 […]